In 2002, Mark Fishman walked into a glass building in Cambridge with an unusual assignment: to turn the Swiss pharmaceutical company, Novartis, into the world’s greatest therapeutics research firm. More unusually still, Fishman was — at least on paper — precisely the wrong man for the job.The Harvard cardiologist had spent his career studying zebrafish hearts and teaching medical students. He had no pharmaceutical experience and no business training. And yet, Daniel Vasella — the physician-turne...